Ionis Pharmaceuticals: Digesting Recent Events

2026-02-27 02:54:16 ET

Shares of antisense therapy concern Ionis Pharmaceuticals, Inc. ( IONS ) have rallied strongly since its familial chylomicronemia syndrome med Tryngolza (olezarsen) bore strong data treating severe hypertriglyceridemia. Announced in September 2025, the results suggest it will be the new standard of care for the indication, prompting management to raise its peak revenue estimate by $1 billion to >$2 billion. The stock fell five percent in trading Wednesday after the company posted Q4 numbers. Management repeated its guidance for peak sales for Tryngolza following fourth quarter results....

Read the full article on Seeking Alpha

For further details see: